Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease. Liquid biopsies, which require just a ...

Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...

Leadoptik today announced the successful first-in-human clinical use of its FDA-cleared Last Inch Assessment (LIA) system.

Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined with ...

RA'ANANA, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, ...

Please provide your email address to receive an email when new articles are posted on . Often regarded in oncology as a complementary diagnostic or early detection tool, liquid biopsy has moved into ...

This results in liquid biopsy to be potentially less expensive as compared to surgical biopsies. Currently, there are several liquid biopsies in development for oncology. These technological ...

Intuitive ISRG announced that the FDA has cleared the integration of mobile cone-beam CT (CBCT) imaging technology with its minimally-invasive, robotic-assisted bronchoscopy system, Ion Endoluminal ...

CAMPBELL, Calif.--(BUSINESS WIRE)--Body Vision Medical, a leader in AI-driven, intraoperative image guidance, today announced that its LungVision® system has been selected as the winner of the “Best ...

For those with cancer, precision oncology promises better treatment plans. It is about allowing treatments to be selected on the basis of genetic signatures, which can reveal specific tumorigenic ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is ...

All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant ...